Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

Stig Ejdrup Andersen; Niels Herluf Paulsen; Per Pfeiffer; Camilla Qvortrup; Per Damkier

Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

Translated title of the contribution: Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine

Stig Ejdrup Andersen, Niels Herluf Paulsen, Per Pfeiffer, Camilla Qvortrup, Per Damkier

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.

Translated title of the contribution	Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine
Original language	Danish
Article number	V07200556
Journal	Ugeskrift for Laeger
ISSN	0041-5782
Publication status	E-pub ahead of print - 8. Feb 2021

Documents & Links

https://ugeskriftet.dk/videnskab/faeno-eller-genotypetest-dihydropyrimidindehydrogenaseman-gel-fluoropyrimidinbehandling

Fingerprint Dive into the research topics of 'Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine'. Together they form a unique fingerprint.

Cite this

@article{39fe231faddc407190a4d9e93214dd05,

title = "F{\ae}no- eller genotypetest for dihydropyrimidindehydrogenase-mangel f{\o}r fluoropyrimidinbehandling",

abstract = "Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.",

author = "Andersen, {Stig Ejdrup} and Paulsen, {Niels Herluf} and Per Pfeiffer and Camilla Qvortrup and Per Damkier",

year = "2021",

month = feb,

day = "8",

language = "Dansk",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

AU - Andersen, Stig Ejdrup

AU - Paulsen, Niels Herluf

AU - Pfeiffer, Per

AU - Qvortrup, Camilla

AU - Damkier, Per

PY - 2021/2/8

Y1 - 2021/2/8

N2 - Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.

AB - Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.

M3 - Tidsskriftartikel

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V07200556

ER -